全文1727字,阅读约需5分钟,帮我划重点划重点01艾美疫苗自主研发的无血清迭代狂犬病疫苗和13价结合肺炎疫苗相继提交上市注册,进入商业化收获期。02无血清迭代狂犬病疫苗有望成为首个上市产品,具有良好的安全性、免疫原性和免疫持久性。0313价结合肺炎疫苗在国内市场具有巨大的上升空间,预计2030年市场规模将达到350亿元人民币。04除此之外,艾美疫苗的全资子公司艾美坚持生物制药有限公司已取得生产...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.